Hers Review: Telehealth GLP-1 Evaluation & Alternatives

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Hers is a direct-to-consumer telehealth platform that connects patients with licensed healthcare providers for weight-management prescriptions, including GLP-1 receptor agonists. The platform has reported serving over 1 million patients across the United States, positioning itself as a convenient alternative to in-person clinic visits for metabolic health consultations.

Choosing a GLP-1 provider involves more than platform convenience—it requires understanding clinical eligibility, medication options, ongoing support, and whether precision diagnostics might enhance treatment personalization. Hers serves a specific market need, yet alternatives including compounded formulations with genetic pathway assessment exist for patients seeking different evaluation depths or cost structures.

How Hers Telehealth Platform Operates for GLP-1 Prescribing

Hers uses asynchronous or synchronous consultations where patients complete health questionnaires and communicate with licensed practitioners—typically nurse practitioners or physician assistants—who review eligibility and issue prescriptions if appropriate. The platform then coordinates medication delivery, often fulfilling prescriptions through its pharmacy network or third-party vendors.

Typical Hers consultations focus on medical history, weight-loss goals, current medications, and contraindications. However, the platform does not routinely offer genetic assessment of peptide pathways or detailed biomarker profiling, relying instead on standard clinical criteria for eligibility and medication selection.

Hers GLP-1 Medication Options and Pricing Structure

Hers offers branded and compounded GLP-1 options, including semaglutide and tirzepatide formulations, with reported monthly costs ranging from approximately $99 to $499 depending on medication type, dosage, and insurance coverage. Hers also provides membership or subscription models that may bundle consultations, medication, and logistics into flat monthly fees.

Pricing transparency on Hers varies by state and insurance status; uninsured patients often pay higher out-of-pocket rates, while those with compatible insurance may see reduced costs. It is important to confirm exact pricing and medication sourcing before enrollment, as compounded versus branded inventory and supplier arrangements differ across regions.

Provider Factor	Hers Approach	PlexusDx Model
Genetic pathway assessment	Not typically included in standard consultation	Optional Precision Peptide Genetic Test ($99 add-on or $298 standalone) revealing GLP1R, GIPR, FTO, MC4R variants
Medication sourcing	Mix of branded and compounded formulations	Licensed 503A compounding pharmacies exclusively; never 503B
Monthly cost range (uninsured)	$99–$499 depending on medication and plan	Compounded semaglutide $149/mo; oral semaglutide $249/mo; compounded tirzepatide $249/mo
Clinical support model	Asynchronous or scheduled telehealth consultations	Telehealth consultation plus optional genetic insight integration

Clinical Eligibility and Medical Evaluation on Hers

Hers typically requires patients to meet standard GLP-1 criteria: BMI ≥30 or ≥27 with weight-related comorbidities, stable cardiovascular health, no personal or family history of medullary thyroid carcinoma, and adequate renal function. Practitioners review questionnaire responses and may request additional medical records or lab results before authorizing prescriptions.

Hers does not mandate baseline biomarkers such as fasting glucose, insulin levels, or inflammatory markers that may predict individual medication response or inform dose escalation strategies. This standardized-criteria approach suits many patients but may miss opportunities for tailored selection if genetic or metabolic context were available.

Genetic Pathways and Peptide Response: A Precision Lens

Recent research highlights genetic variants in GLP-1 receptor (GLP1R), glucose-dependent insulinotropic peptide receptor (GIPR), fat mass and obesity associated gene (FTO), and melanocortin-4 receptor (MC4R) that may correlate with baseline BMI, weight-loss trajectory, and side-effect tolerability. Understanding an individual's genetic architecture in these pathways may support more informed medication selection and dose titration, though genetic predisposition does not determine exact treatment outcomes.

PlexusDx offers a Precision Peptide Genetic Test that identifies common variants in these peptide-metabolism genes, potentially adding context to a provider conversation about whether standard GLP-1 dosing, microdose protocols, or combination therapies may align better with an individual's genetic profile. This assessment complements—not replaces—clinical judgment and standard medical evaluation.

Safety Monitoring and Adverse Event Management

Hers providers conduct baseline screening for contraindications and advise patients on common GLP-1 side effects including nausea, vomiting, constipation, and rare pancreatitis risk. However, ongoing safety monitoring on Hers depends on patient-initiated check-ins rather than mandatory follow-up labs or clinical assessments, which may delay detection of dose-related complications or emerging health concerns.

Patients using GLP-1 medications should maintain contact with their Hers provider and a primary care physician to coordinate care, report persistent side effects, and address any signs of dehydration, acute abdominal pain, or thyroid symptoms. Compounded formulations from licensed 503A pharmacies also require proper handling and storage verification to ensure medication integrity.

How PlexusDx Supports a More Personalized Approach

PlexusDx compounded GLP-1 options from licensed 503A pharmacies offer an alternative to Hers' mixed branded/compounded inventory, with pricing starting at $179/month for compounded semaglutide. The platform emphasizes transparency around sourcing and may appeal to patients seeking lower-cost or customized formulations without compromising safety or regulatory oversight.

The Precision Peptide Genetic Test available through PlexusDx may help provide context about an individual's genetic predispositions in peptide metabolism pathways—including GLP1R, GIPR, FTO, and MC4R variants—supporting conversations with providers about whether standard protocols, microdose approaches, or combination compounds align with genetic architecture. This genetic insight is not a guarantee of medication response but rather a data point to inform personalized planning.

Patients comparing Hers with PlexusDx should consider whether their primary need is convenience and speed (Hers strength), cost savings and compounding precision (PlexusDx strength), or genetic pathway insight for more targeted medication selection. Neither platform replaces in-person medical oversight; integration with a primary care provider remains essential for safe, coordinated GLP-1 therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is Hers and who is it designed for?

Hers is a telehealth platform connecting patients with licensed practitioners for remote weight-management consultations and GLP-1 prescriptions. It is designed for adults seeking convenient, non-clinical-visit access to GLP-1 medications and is most useful for those comfortable with asynchronous digital consultations.

Does Hers include genetic or biomarker testing?

Hers does not routinely include genetic assessment of peptide pathways or detailed biomarker profiling. Eligibility is determined by standard clinical criteria rather than genetic predisposition. Patients interested in genetic insights may explore additional testing through other platforms.

How does Hers pricing compare to PlexusDx compounded options?

Hers ranges $99–$499/month depending on medication and insurance; PlexusDx compounded semaglutide starts at $179/month and tirzepatide at $229/month. PlexusDx also offers a Microdose GLP-1 Protocol at $129/month for patients seeking lower-dose initiation.

Is Hers safe, and what monitoring is provided?

Hers conducts baseline safety screening and advises on GLP-1 risks. However, ongoing monitoring depends on patient-initiated check-ins rather than mandatory follow-up labs. Patients should maintain parallel contact with a primary care provider for comprehensive safety oversight.

Can genetic testing improve GLP-1 medication selection?

Genetic variants in GLP1R, GIPR, FTO, and MC4R may correlate with weight-loss response and side-effect patterns. PlexusDx Precision Peptide Genetic Test ($99 add-on) can reveal these variants, supporting more informed provider conversations, though genetic predisposition does not guarantee outcomes.

Hers Review: Clinical Assessment of Telehealth GLP-1 Access